PROSTATE CANCER

This study tests two drugs, saruparib and darolutamide, given alone or together before prostate removal surgery in men with newly diagnosed prostate cancer. The goal is to see how these drugs affect cancer cells and check for side effects. About 120 men with localized, higher-ris…

This study tests whether adding darolutamide to standard hormone therapy (ADT) helps Chinese men with a high-risk form of prostate cancer that has not spread but is no longer responding to hormone therapy alone. Darolutamide blocks the effects of male hormones on cancer cells, po…

This trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prosta…

This study tested whether giving a higher dose of radiation specifically to the visible tumor inside the prostate could improve cancer control in men with localized prostate cancer. Eighty-five men either received a standard radiation plan with an extra boost to the tumor or a co…

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This completed phase II trial tested whether a targeted chemotherapy drug (abemaciclib) and an immunotherapy drug (atezolizumab), alone or together, can shrink or slow advanced prostate cancer that no longer responds to hormone therapy. Nineteen men with metastatic castration-res…

This early-stage study tests two oral drugs (darolutamide and abemaciclib) plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second checks if the combination can shrink or eliminate tumo…

This completed Phase 3 study compared the risk of major heart problems between two hormone therapies—relugolix (a pill) and leuprolide (an injection)—in 387 men with prostate cancer. The trial was stopped early by the sponsor, but enrolled patients could continue treatment for up…

This study tested a drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The drug works by blocking male horm…

This study tested a device called NanoKnife to treat prostate cancer in 121 men with intermediate-risk disease. The goal was to safely destroy cancer tissue while avoiding major side effects. Researchers checked if the treated area was cancer-free after 12 months and tracked any …

This phase II trial tested a combination of three drugs—carboplatin, cabazitaxel, and abiraterone—in 61 men with high-volume metastatic prostate cancer that still responds to hormone therapy. The goal was to see how many men had no cancer growth after one year. The study also tra…

This early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…

This study followed 354 men with low- to intermediate-risk prostate cancer who chose to freeze only the cancerous half of their prostate (hemi-gland cryoablation). Researchers tracked how well the treatment controlled the cancer and how it affected urinary function and quality of…

This study tested a new X-ray monitoring technique (KIM) during prostate cancer radiation therapy. The goal was to see if it helps doctors aim more precisely at the tumor while reducing harm to healthy tissue. 49 men with low- or intermediate-risk prostate cancer took part. The a…

This phase I trial tested a new type of radiation therapy for low- and intermediate-risk prostate cancer that delivers a higher dose each day, completing treatment in just 5 sessions over 2 weeks instead of the usual 45-48. The study enrolled 120 participants to check the safety …

This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 8 men whose prostate cancer had returned after surgery or radiation, shown by rising PSA levels. The men had specific genetic changes (MMR deficiency or CDK12 alteration) that might make their cancers more sen…

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…

This trial tested whether a precise type of radiation called SBRT could slow the growth of metastatic prostate cancer in men whose disease was starting to worsen despite hormone therapy. 86 men with one or two growing tumors received SBRT while continuing their current hormone dr…

This study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…

This study tested a radioactive drug called 177Lu-PSMA-617 in 94 Japanese men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers measured how well it shrank tumor…

This study tested a device that uses water vapor (steam) to destroy cancerous tissue in the prostate. 32 men with prostate cancer received the treatment just before their scheduled prostate removal surgery. Researchers checked how well the steam destroyed the targeted tissue and …

This study tested whether adding a prostate cancer vaccine (PROSTVAC) and chemotherapy (docetaxel) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. 74 men with metastatic castration-sensitive prostate cancer took part. …

This study tested whether adding a radioactive drug (radium-223) to standard targeted radiation (SBRT) can delay cancer progression in men whose prostate cancer has returned in a few bone spots but hasn't yet become hormone-resistant. Twelve men participated, receiving either the…

This early study tested a new laser treatment for prostate cancer that can be done in a doctor's office. Ten men with early-stage prostate cancer received focal laser ablation guided by MRI and ultrasound images. The main goal was to see if the procedure is safe and feasible, not…

This study tested a single, high-dose radiation treatment for men with low-risk or low intermediate-risk prostate cancer. The goal was to see how well the body tolerates this one-time treatment by tracking side effects in the bladder and digestive system within the first 6 months…

This study compared two types of radiation therapy for men with intermediate-risk prostate cancer: standard image-guided external beam radiation (IGRT) versus IGRT plus a high-dose-rate brachytherapy boost. The goal was to see which treatment works better and what side effects oc…

This study tested whether giving two drugs together—Radium-223 and enzalutamide—is safe for men with advanced prostate cancer that has spread to other parts of the body and is no longer controlled by standard hormone therapy. 45 men took part. The main goal was to track serious s…

This study tested whether giving three hormone-blocking drugs along with high-dose, precisely targeted radiation could stop very high-risk prostate cancer from coming back. Sixty-four men with aggressive prostate cancer received the treatment. The main goal was to see how many me…

This study tested a new way to treat intermediate-risk prostate cancer using a 3D map to guide microwaves directly to the main tumor. 76 men across Europe received the treatment, and researchers checked if the cancer was gone after 12 months. The goal is to destroy the cancer whi…

This early-phase study tested a new combination of two drugs—enzalutamide and relacorilant—in 42 men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check safety and see how the drugs interact in the body. Researchers also…

This early-phase trial tested whether rituximab, a drug that depletes B cells, could reduce immune cell infiltration in prostate tumors. Eight high-risk prostate cancer patients received four weekly doses before their scheduled prostate removal. The main goal was to see if B-cell…

This large phase 3 trial studied 1,538 men with intermediate-risk prostate cancer. It compared dose-escalated radiation therapy alone versus radiation plus short-term (6 months) androgen deprivation therapy (hormone therapy). The goal was to see if adding hormone therapy improves…

This study looked at 588 men with intermediate-risk prostate cancer to see if adding external beam radiation to brachytherapy (placing radioactive seeds in the prostate) works better than brachytherapy alone. The goal was to see which approach better controls the cancer over time…

This Phase 3 trial tested whether adding the drug TAK-700 to standard hormone therapy and radiation could better control high-risk prostate cancer. 239 men participated. The study compared standard treatment (GnRH agonist plus anti-androgen) with an enhanced version that also inc…

This phase 2 trial tested a drug called Lutetium-177-PSMA-617, which delivers radiation directly to prostate cancer cells. It included 58 men with prostate cancer that had spread to a few spots in bones or lymph nodes but was still hormone-sensitive. The study compared the drug t…

This study tested a shorter course of proton radiation (5 treatments over 2 weeks) for men with localized prostate cancer, compared to the usual 8 weeks. The goal was to see if this approach maintains quality of life and controls the cancer. 150 men with low- to intermediate-risk…

This study tested a combination of abiraterone acetate and prednisone in 131 men with advanced prostate cancer that had not yet spread on scans. The goal was to see if the drugs could lower PSA levels and delay cancer progression. Participants took daily pills alongside standard …

This study tested a treatment called focused ultrasound (HIFU) that aims to destroy only the cancerous part of the prostate, avoiding common side effects like incontinence and impotence from standard treatments. It involved 174 men aged 50-80 with intermediate-risk prostate cance…

This Phase 2 study tested a radiation therapy plan that gives a slightly higher dose each day over fewer sessions (16 days instead of the usual 8-9 weeks) for men with early-stage prostate cancer. The goal was to see if this shorter schedule is safe and effective, while also trac…

This study tested a combination of high-dose radiation and hormone therapy (leuprorelin) in 74 men with prostate cancer that had returned in up to 5 pelvic lymph nodes after initial treatment. The goal was to see if this approach could delay further cancer growth or relapse. Part…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…

This study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…

This study tested the immunotherapy drug nivolumab (Opdivo) combined with one of three other drugs (rucaparib, docetaxel, or enzalutamide) in 292 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to see if these combinations…

This study tested a drug called enzalutamide in 1401 men with a type of prostate cancer that has not spread to other parts of the body but is no longer controlled by standard hormone therapy. The goal was to see if enzalutamide could delay the cancer from spreading. Participants …

This study tested whether adding focused radiation to standard hormone therapy or chemotherapy helps men with prostate cancer that has spread to a few spots (oligometastatic) and is no longer responding to hormone therapy alone. Fourteen participants received either standard trea…

This study tested whether a device called the Pelvic Clock® helps men recover bladder control and sexual function faster after robotic prostate cancer surgery. Sixty men aged 55 to 80 used either the device plus standard exercises or standard exercises alone. The main goal was to…

This study tested whether adding the drug TAK-700 to standard hormone therapy helps men with newly diagnosed prostate cancer that has spread live longer than adding the drug bicalutamide. Over 1,300 men took part. The goal was to see which combination works better for controlling…

This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors or slow progression in men with metastatic castration-resistant prostate cancer. 351 participants received either the combination, ipilimumab alone, or the chemother…

This study looked at the long-term safety of the drug degarelix in 57 men with prostate cancer. Participants received a monthly injection of degarelix for up to 5 years. The goal was to monitor side effects, such as changes in blood pressure, pulse, weight, and liver function.

This phase 3 study tested whether adding apalutamide (Erleada) to standard hormone therapy (LHRH analogues) can delay cancer progression in men whose prostate cancer has returned after surgery. 504 men with rapidly rising PSA levels took part. The goal was to see if the combinati…

This study tested whether adding a radioactive drug (Radium-223) to targeted radiation (SABR) helps men with prostate cancer that has spread to a few bones or soft tissues. 64 men participated, receiving either SABR alone or SABR plus Radium-223. The goal was to see if the combin…

This study looked at a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The study was completed…

This study tested a new way to treat low-risk prostate cancer using MRI-guided laser ablation. Seven men with early-stage prostate cancer received the treatment to see if it was safe and could successfully destroy tumors. The goal was to target only the cancer while avoiding side…

This small pilot study tested a procedure called prostatic arterial embolization in 10 men with low-risk, one-sided prostate cancer who were already on active surveillance. The idea was to block the artery feeding the tumor, starving it of blood. Researchers checked for side effe…

This early-phase trial tested whether injecting a man's own bone marrow stem cells into the penis could help restore erections after prostate cancer surgery. The study included 18 men who had normal erections before surgery but developed erectile dysfunction due to blood vessel d…

This study tested a cancer vaccine called ETBX-011 in 43 people with advanced colorectal, lung, breast, or prostate cancers that produce a protein called CEA. The vaccine uses a modified virus to teach the immune system to attack cancer cells making CEA. The main goals were to ch…

This early-phase study tested a new treatment schedule for men with castration-resistant prostate cancer. The approach alternates between giving testosterone through the skin and the drug enzalutamide, aiming to control the disease. The main goals were to see if this schedule is …

This study looked at whether eating a whole food plant-based diet for six months can help men with prostate cancer whose PSA levels are rising. Eleven men attended cooking classes and ate mostly plants. Researchers measured changes in PSA, cholesterol, blood sugar, and inflammati…

This early-phase study tested a highly targeted type of radiation (SBRT) in 17 men whose prostate cancer returned after prior radiation. The goal was to find the highest safe dose and see how well the body tolerated it. Participants received five focused treatments over two weeks…

This study tested different combinations of immunotherapy drugs in 59 adults with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if these combinations are safe and can help shrink tumors or lower PSA levels. Participants received up to fo…

This study tested a two-step treatment in 15 men with metastatic castration-resistant prostate cancer. First, they took high-dose oral testosterone for three 28-day cycles. If the cancer grew, they switched to enzalutamide. The goal was to see if oral testosterone could control t…

This study looked at a small implantable spacer placed between the prostate and rectum in men receiving radiation for prostate cancer. The goal was to see if the spacer reduces the radiation dose reaching the rectum, potentially lowering side effects. A total of 175 men who alrea…

This completed study tested a hydrogel spacer placed between the prostate and rectum in 20 men undergoing radiation for prostate cancer. The goal was to see if the spacer reduces radiation reaching the rectum. Researchers compared rectal radiation exposure before and after insert…

This study tested a combination of two drugs, apalutamide and abiraterone, plus prednisone, in 93 men with advanced prostate cancer that had spread and was no longer responding to hormone therapy. The goal was to see how long the cancer stayed under control and whether the drugs …

This early study tested whether adding a radioactive drug (177Lu-PSMA) to standard brachytherapy is safe and feasible for men whose prostate cancer returned after initial radiation. Only 3 men took part. The goal was to see if the combination could control cancer both in the pros…

This study looked at men with advanced prostate cancer that no longer responds to hormone therapy. When the standard dose of abiraterone stopped working, some patients received a double dose to see if it could stabilize the disease. The goal was to find out if this approach is sa…

This pilot study tested high dose rate brachytherapy, a type of internal radiation, in 43 patients with cervical, endometrial, esophageal, prostate, or biliary cancer. The goal was to see if the radiation implants could deliver the planned dose accurately. Participants received b…

This completed phase 1 trial tested a radioactive imaging agent called [99mTc]Tc-DB8 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help detect tumors using SPECT scans. Researchers also checked for safety and…

This completed phase 1 study tested a new radioactive imaging agent called 99mTc-RM26 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors using SPECT scans. Researchers also checked for safety and …

This completed Phase 1 study tested a new radioactive tracer called [99mTc]Tc-BQ0413 in 10 men with prostate cancer. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it goes in the body and how safe it is. The goal is to develop a better imaging…

This completed Phase 2 trial tested an imaging dye called Cytalux (pafolacianine) in 9 men with prostate cancer. The dye is injected before surgery and makes cancer cells glow under near-infrared light, helping surgeons see and remove all cancerous tissue during prostate removal.…

This study tested a new MRI method that measures temperature changes in the prostate. The goal is to help doctors find cancer more accurately and guide laser treatments. Researchers scanned 70 men who already needed an MRI for prostate cancer diagnosis. The focus was on checking …

This completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …

This study tested an AI software called Quantib Prostate to see if it can detect prostate cancer on MRI scans as accurately as expert radiologists. Researchers looked at 200 men who had prostate MRIs and biopsies. The AI's readings were compared to the radiologist's readings, usi…

This study tested whether specially trained dogs can identify breast, lung, prostate, or colorectal cancer by sniffing breath samples collected on masks. Over 1,300 people provided breath samples before their regular cancer screening or biopsy. The dogs' results were compared to …

This study tested two different radioactive tracers (68Ga-RM2 and 68Ga-PSMA-617) used in PET/CT scans to see which one better detects prostate cancer in men scheduled for prostate removal surgery. Twenty-two men with low, intermediate, or high-risk prostate cancer received both s…

This study compared two radioactive tracers, piflufolastat (18F) and flotufolastat (18F), used in PET scans to detect prostate cancer that has returned after surgery. The main goal was to see which tracer produces less radioactivity in the bladder, which can interfere with image …

This study tested whether an artificial intelligence (AI) system could help find prostate cancer on MRI scans. 365 men who needed a prostate biopsy had their MRI images reviewed by both the AI and by senior radiologists. Doctors then performed targeted biopsies on any suspicious …

This study looked at 60 men who had a prostate biopsy to check for cancer. It compared two imaging methods used to guide the biopsy: the standard multiparametric MRI and a newer scan called Ga-68 PSMA PET/CT. The goal was to see which method better finds aggressive prostate cance…

This study tested a new type of PET-CT scanner that can scan a tumor right after it is removed from the body. Patients with prostate or head and neck cancer received a small amount of radioactive tracer before surgery, which sticks to cancer cells. After removal, the specimen was…

This study tested a new imaging technique called Full Field Optical Coherence Tomography (FFOCT) to see if it can detect prostate cancer in biopsy samples as well as standard microscope analysis. Researchers compared FFOCT results to the usual pathology exam in 91 men with elevat…

This Phase 3 study tested a radioactive tracer called Copper Cu 64 PSMA I&T, given as an injection, to improve PET/CT scans in 235 men with prostate cancer that may have returned after initial treatment (surgery or radiation). The goal was to see how accurately the scan could det…

This study tested a new type of PET scan using a radioactive tracer called 89Zr-DFO-huJ591 to find prostate cancer that has spread to other parts of the body. 77 men with metastatic prostate cancer received the experimental scan, and some also had standard scans and biopsies for …

This early-phase trial tested a new radioactive imaging agent called rhPSMA-7.3 (18F) in 24 people: some healthy volunteers and some with prostate cancer. The goal was to check safety and see how the agent spreads in the body and how well it lights up cancer on PET scans. The stu…

This study tested a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal was to see if it is safe and to measure how much radiation the body receives. The agent helps doctors see where cancer has spread using a special scan.

This study collected blood and urine samples from 61 men with prostate cancer and healthy volunteers to look for cancer DNA. The goal is to develop a non-invasive way to detect and track prostate cancer without needing a biopsy. Researchers compared genetic material from cancer p…

This study compared two ways to biopsy the prostate in 275 men with suspected cancer. The standard method takes random samples from the gland, which can miss aggressive tumors or find harmless ones. The new method uses MRI images to guide the needle to suspicious spots. The goal …

This study tested whether new deep learning (AI) technology can make prostate MRI scans faster while still finding suspicious nodules. Researchers compared standard MRI sequences with faster, AI-enhanced versions in 34 adults referred for prostate MRI. The goal was to see if the …

This study tested whether using an MRI to guide prostate biopsies could detect cancer as well as the standard 12-sample systematic biopsy. Researchers enrolled 108 men aged 45-75 with elevated PSA levels and suspicious MRI findings. They compared the cancer detection rates of 3 t…

This study explored whether prostate cancer cells can be detected in blood samples instead of using a needle biopsy. Researchers collected blood from 127 men with suspected prostate cancer and used a special filter to isolate tumor cells. The goal was to see if this non-invasive …

This study tested a simple, rapid PSA blood test that gives results in minutes, comparing it to the standard lab PSA test. Researchers enrolled 94 men with prostate cancer or benign prostate disease. The goal was to see if the quick test is accurate enough for screening. If it wo…

This study tested whether a new, high-resolution ultrasound (micro-ultrasound) can find aggressive prostate cancers as well as MRI does during biopsy. Over 800 men with suspected prostate cancer were randomly assigned to one of three biopsy guidance methods. The goal was to see w…

This completed Phase 3 study tested a new radioactive tracer called [18F]CTT1057 for PET/CT scans in 190 men with prostate cancer whose PSA levels were rising after initial treatment. The goal was to see if the tracer could accurately locate where the cancer had returned. Partici…

This study tested a new imaging agent called [18F]CTT1057 for PET scans to see how well it can find prostate cancer tumors. 195 men with high-risk prostate cancer who were scheduled for surgery received the scan. The results were compared to tissue samples taken during surgery to…

This study tested a new imaging agent called 68Ga-NTA-476 for PET scans in 10 men with prostate cancer. The goal was to see how well it finds tumors compared to the standard scan, and to check for side effects. This was the first time this agent was used in humans, so safety and …

This phase 3 study tested a new radioactive imaging agent, rhPSMA-7.3 (18F), in 391 men with suspected prostate cancer recurrence after initial treatment. The agent is used during a PET scan to highlight cancer cells. The goal was to see how well it detects where the cancer has r…

This completed study collected urine and blood samples from 80 men, including those with prostate cancer, suspected cancer, or benign prostate enlargement, as well as healthy donors. The goal was to find RNA biomarkers that could lead to a simple liquid biopsy test for diagnosing…

This study tested a fluorescent dye called IS-002 that makes prostate cancer cells glow under special lights during robotic surgery. Fifty-nine men with prostate cancer received the dye before surgery, and surgeons used a special camera to see the glowing areas. The goal was to s…

This completed study tested an artificial intelligence model called BEAM that combines MRI scans with a blood test (cell-free DNA) to improve prostate cancer diagnosis. Over 1,600 men participated, including those with healthy prostates, benign enlargement, or prostate cancer. Th…

This study tests whether placing ice inside the rectum before a prostate biopsy can lower pain, anxiety, stress hormone levels, and complications like bleeding. About 84 men having their first prostate biopsy will either receive standard care or ice application. The goal is to se…

This small pilot study tested a 3-month program where men with prostate cancer on hormone therapy were encouraged to fast for 12 to 16 hours each night, supported by weekly coaching calls and text messages. The 40 participants found the program feasible and satisfying, with some …

This study tested a program to help men prepare for and manage side effects from prostate cancer treatments like surgery or radiation. The program used daily texts and emails, plus support from other men, to encourage healthy habits before treatment. The goal was to reduce distre…

This study tested whether a prehabilitation program—including exercise, nutrition advice, and education—before robotic prostate surgery helps men regain quality of life more quickly. One hundred men with localized prostate cancer participated. The goal was to see if preparing the…

This small pilot study tested whether acupuncture could help reduce hot flashes and night sweats in men with prostate cancer who are on hormone therapy. Twelve men received acupuncture sessions, and researchers measured how well the treatment was accepted and whether symptoms imp…

This study tested a stepped-care telehealth program for cancer survivors living in rural areas who experience anxiety, depression, or sleep problems. Participants received either low-intensity check-ins or high-intensity phone therapy with a licensed therapist, depending on sympt…

This study looked at whether giving a lower dose of the steroid dexamethasone before the chemotherapy drug docetaxel can prevent allergic reactions with fewer side effects. The standard high dose can cause problems like high blood sugar, mood changes, and weakened immunity. Resea…

This study tested whether buffered lidocaine (lidocaine mixed with baking soda) reduces pain during prostate biopsy. 350 men undergoing a prostate biopsy received either buffered or standard lidocaine. Researchers measured pain from the numbing injection and from the biopsy itsel…

This study tested a web-based program called True North Peer Navigation for men recently treated for prostate cancer. 184 men were randomly assigned to get a trained peer navigator or usual care. The program aimed to help men take a more active role in their health and improve qu…

This study tested whether a TENS device, which uses mild electrical pulses, can reduce pain during a prostate biopsy. 84 men were randomly assigned to receive TENS plus local anesthetic, a sham TENS device plus local anesthetic, or local anesthetic alone. Participants reported th…

This study looked at whether acupuncture can reduce pain and anxiety in men undergoing a prostate biopsy. 72 men were randomly assigned to receive either real acupuncture or a sham (fake) version before the procedure, in addition to standard numbing medicine. The main goal was to…

This study tested whether adding spinal anesthesia to standard general anesthesia helps men recover faster and feel less pain after robotic prostate cancer surgery. Thirty men took part in this double-blind, placebo-controlled trial. The main goal was to see how quickly they coul…

This completed Phase I safety trial tested whether using the UroLift system—a device that lifts and holds enlarged prostate tissue out of the way—before stereotactic ablative body radiotherapy (SABR) is safe for men with both prostate cancer and benign prostatic hyperplasia (BPH)…

This study tested a remote exercise program for 27 men with prostate cancer who were receiving hormone therapy (androgen deprivation therapy). The program included walking or cycling, strength training, and counseling sessions over 8 weeks. The main goal was to see if the program…

This completed Phase 2 trial tested whether formal hypnosis, alongside standard care, could reduce anxiety and pain in 68 cancer patients undergoing brachytherapy. Patients received either standard care with Kalinox or standard care plus formal hypnosis. The study measured anxiet…

This study tested whether watching 360° virtual reality movies can reduce fear and anxiety in cancer patients about to start radiation therapy. 292 adults with breast, lung, prostate, head and neck cancer, or brain tumors participated. Patients watched a VR movie and then filled …

This pilot study tested a behavioral program called PROWESS for Black and Hispanic men with prostate cancer who are on hormone therapy (ADT). The program included video or in-person sessions with a psychologist or social worker and a FitBit to track activity. The goal was to see …

This phase 2 trial tested whether testosterone replacement therapy could safely improve symptoms like low sex drive and fatigue in 136 men who had their prostate removed for low-risk prostate cancer. Participants received weekly testosterone injections or a placebo for 12 weeks. …

This pilot trial tested a behavioral program called ActiveHeal EST in 30 adults recently diagnosed with breast or prostate cancer. The program includes group sessions and home activities to help survivors persist in daily tasks despite challenges. Researchers measured changes in …

This study tested two drugs used to reverse muscle relaxants after surgery: sugammadex and a combination of neostigmine and glycopyrrolate. The goal was to see which one better prevents urinary retention in 124 patients having ear, nose, or throat surgery who were at high risk du…

This study looked at whether showing patients a dynamic video before a prostate biopsy could lower their pain and anxiety compared to just verbal instructions or static images. 223 men aged 50-80 with elevated PSA levels participated. Pain was measured with a Visual Analog Scale …

This study tested two types of nerve blocks—Quadratus Lumborum (QL) and Erector Spinae (ESP)—to see which provides better pain relief after abdominal surgery. 100 adults having surgery for colorectal, prostate, or kidney cancer, or gallbladder removal, received one of the blocks …

This study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …

This study looked at whether it is safe to skip antibiotics before a prostate biopsy. Researchers followed 1753 men who had a biopsy through the perineum (the area between the scrotum and anus). They compared infection rates in those who did not get antibiotics to existing data f…

This study looks at whether a special type of PET scan, using two different tracers, can help predict how aggressive a person's prostate cancer is before surgery. Researchers will use computer models to analyze the scan images and compare the results with standard biopsy and surg…

This study looked at how two prostate cancer drugs, darolutamide and enzalutamide, affect thinking and memory in men with advanced prostate cancer. About 111 men took one of the two drugs and completed computer-based cognitive tests over time. The goal was to see if one drug caus…

This study created a massive, secure database of over 14,000 prostate MRI scans from men with or suspected of having prostate cancer. Researchers used this data to train artificial intelligence (AI) models to better tell apart slow-growing from aggressive cancers, predict if canc…

This study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal …

This early-stage study tested the safety of a single dose of an Angelica herbal supplement (AGN-Cogni.Q) in 12 men aged 40 and older with prostate cancer. Researchers checked heart health and blood tests for any side effects, and measured how the supplement's compounds move throu…

This early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identi…

This study looked at two ways of giving anesthesia during robotic prostate removal surgery. One method used a low flow of gas (1 liter per minute) and the other used a normal flow (3 liters per minute). The goal was to see which one is better for breathing, heart function, and co…

Researchers at Stanford University tested a new micro-ultrasound device to see if it can more accurately find and outline prostate cancer. The study involved 95 men scheduled for biopsy or prostate removal. The ultrasound images were compared with standard pathology results to he…

This completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…

This study looked at 30 men with prostate cancer to understand why MRI and PSMA-PET scans sometimes spot different tumors. Researchers used stored tissue samples to analyze the genes and molecules of these mismatched lesions. The goal was to find out if these differences mean the…

This study looked at 185 men with low-risk prostate cancer who chose active surveillance (monitoring instead of immediate treatment). Researchers used a genetic test called a polygenic risk score to see if it could predict which men would have their cancer get worse over time. Th…

This pilot study tested whether a special 2D antiscatter grid can improve the quality of cone-beam CT (CBCT) images used during radiation therapy for prostate, head and neck, and upper abdomen cancers. 43 participants received one extra CBCT scan with the grid, and researchers co…

This study looked at how prostate and colorectal cancer affect mitochondria—the energy factories in cells—and whether a 4-week home exercise program could improve them. Fifteen men awaiting surgery did either resistance or high-intensity interval training at home. Researchers mea…

This study tested an online decision aid called 'Talk to Nathan About Prostate Cancer Screening' in 88 men aged 55-69. The goal was to see if it improved knowledge and helped men make clearer decisions about screening compared to standard materials. Participants used the tool or …

This study looked at how often a specific gene change (called HOXB13 c.853delT) occurs in men with prostate cancer in Martinique. Researchers tested 465 men of African descent who had prostate cancer. The goal was to find out how common this gene change is, which may help underst…

This study looked at how closely 200 adults with advanced breast or prostate cancer follow their prescribed oral cancer treatments. Participants filled out questionnaires about their medication use and gave blood samples to check certain health markers. The goal was to understand…

This study looked at whether an educational session about orchiectomy (surgery to remove the testicles) would make more men with prostate cancer choose it over lifelong hormone therapy. 101 men who were already on hormone therapy for at least a year took part. The goal was to see…

This completed study surveyed 51 men with localized prostate cancer and their healthcare providers in Belgium, Italy, and Spain. The goal was to understand how acceptable artificial intelligence (AI) is as a tool to help diagnose prostate cancer, and whether people are willing to…

This study looked at nearly 1,000 cancer survivors to find out which follow-up care model works best for their quality of life and satisfaction. Participants were breast, prostate, or colorectal cancer survivors who had finished active treatment. Researchers compared different ca…

This study looked at 50 men having robot-assisted prostate surgery to compare two ways of using a breathing machine: flow-controlled and volume-controlled ventilation. The goal was to see which method keeps oxygen levels better and helps the lungs work more smoothly. Researchers …

This study looked at 168 men with metastatic hormone-sensitive prostate cancer to see if a model using PSMA-PET scans and routine medical information could predict how well they would respond to standard first-line treatment. The goal was to help doctors better understand which p…

This study looked at over 1,200 men with advanced prostate cancer who received a radioactive drug called Lutetium-177 vipivotide tetraxetan in real-world clinics. Researchers tracked patient characteristics, treatment patterns, and PSA level reductions. The goal was to see how th…

This study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…

This study examined medical records of over 6,400 prostate cancer patients who received a treatment called 177Lu-PSMA-617. Researchers wanted to understand the patients' characteristics, treatment patterns, and survival outcomes. The study did not test a new treatment but instead…

This study looked at men whose prostate cancer came back after surgery, shown by a small rise in PSA. It compared giving radiation right away versus waiting and doing another special scan when PSA rose higher. Only 4 men took part, so the main goal was to see if such a study is e…

This study tested a special PET scan tracer called 18F-FAZA to find low oxygen areas (hypoxia) in prostate tumors. Hypoxia can make cancer harder to treat with radiation or chemo. The study involved 18 men with intermediate to high-risk or metastatic prostate cancer. The goal was…

This pilot study tested a web-based tool called MAP (Management of Active surveillance in Prostate Cancer) in 39 men aged 55+ with low-risk prostate cancer who were already on active surveillance. The tool provides education, helps coordinate care with primary care doctors, and o…

This study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatb…

This study looked at 10 men to understand why androgen deprivation therapy (ADT) for prostate cancer can lead to high blood pressure. Researchers checked if problems with the nervous system or kidneys were to blame. The goal is to find ways to prevent heart disease in prostate ca…

This study followed 25 men who carry BRCA1 or BRCA2 gene mutations (and a control group of non-carriers) to see if they developed prostate cancer. Researchers called participants to update their medical history and check for new diagnoses. The goal is to learn how to better scree…

This study tested a new education program for men with metastatic prostate cancer who are taking next-generation hormone therapy. The program aimed to help patients better understand their disease, stick to their medication, and improve their quality of life. 18 patients took par…

This study analyzed blood samples from 33 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers looked for tiny molecules called microRNAs that might predict whether a patient will resist chemotherapy or newer hormone drugs. The goal is to help…

This completed study at Yale University enrolled 600 men with prostate cancer to test a new biopsy method that combines MRI and ultrasound images. The goal was to collect extra tissue samples for detailed single-cell analysis, looking at proteins and other markers to better predi…

This study looked at whether a blood test measuring how certain immune cells die after radiation can predict long-term side effects in breast and prostate cancer patients. Researchers enrolled 885 participants and tracked late complications. The goal is to personalize treatment t…

This completed study involved 100 men aged 40 and older, with no personal history of prostate cancer, to understand their beliefs about genetic risk for the disease. Participants filled out a questionnaire and were asked to provide a saliva sample for genetic testing. The goal wa…

This study measured how often muscle loss (sarcopenia) happens in men aged 70 and older with prostate cancer who are treated with radiation and hormone therapy. Researchers screened 112 patients using a simple questionnaire and body scans. The goal was to understand risk factors …

This study followed 831 men aged 60 and older with prostate cancer who were starting GnRH agonist therapy (a type of hormone therapy). Researchers measured how their quality of life changed over 6 months, comparing different age groups. The goal was to understand how age affects …

This study tested new guidelines for PSA screening to help doctors decide when to start and stop screening, how often to repeat it, and when to refer for biopsy. Researchers also provided patient navigation for men with elevated PSA levels. The goal was to see if these steps coul…

This study tested a program called KanSurvive, which uses virtual education sessions and practice support to help rural primary care clinics improve follow-up care for cancer survivors. Researchers worked with 15 rural practices to see if they could better follow guidelines for m…

This pilot study tested whether a brief educational session with a trained educator could increase the number of men with prostate cancer who agree to germline (inherited) genetic testing. The study enrolled 50 men who met national guidelines for testing but had not yet been test…

This study looked at gene activity in prostate tissue from 867 men to learn how genes relate to prostate cancer development and growth. Researchers collected tissue samples from men having prostate biopsies or surgery. The goal was to link genetic patterns with patient outcomes, …

This study gathered information and samples from 382 men with low-grade prostate cancer to create a tool that can better predict if the cancer is actually more aggressive than it appears. The goal is to help doctors and patients make more informed decisions about treatment. Parti…

This study tested whether combining PET-CT and MRI scans (called trimodality imaging) can better define the target area for radiotherapy in high-risk prostate cancer. Twenty patients received both standard scans and the new combined scan before treatment. Researchers compared the…

This study tested whether a multimedia educational program helps African American men and their doctors make better decisions about PSA screening for prostate cancer. 161 African American men aged 40-69 took part. Half received the program, half got usual care. The goal was to se…

This study surveyed 109 men with prostate cancer and women with breast cancer who were starting radiation therapy. Researchers asked about their use of complementary and alternative medicines (CAM), such as nutritional supplements, at three different times to see if their habits …

This study looked at whether a special 3D camera can accurately measure radiation from a prostate cancer drug called lutetium. Researchers used data from 20 patients who had already received the treatment. The goal was to see if images taken at different energy levels give the sa…

This study tested a special barbed suture (Symmcora Longterm) used to reconnect the bladder after robotic prostate removal for prostate cancer. Researchers measured how long the stitching took and checked for leaks or other problems up to 6 months after surgery. The goal was to s…

This study compared two common methods for taking a prostate biopsy: one through the rectal wall and one through the skin between the scrotum and anus. 840 men who needed a biopsy for suspected prostate cancer were randomly assigned to one of the two methods. The goal was to see …

This completed study collected MRI and 3D ultrasound images from 2 men with prostate cancer who had their prostate removed. The goal was to create a database that could later be used to train a computer system to detect cancer without needing a biopsy. This is a very early step i…

This study looked at a newer way to take prostate tissue samples using MRI guidance through the perineum (the area between the scrotum and anus) instead of the standard method through the rectum. The goal was to see if this approach causes fewer complications and hospital readmis…

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This study analyzed medical records of 507 U.S. veterans with prostate cancer who started taking the drug relugolix between 2020 and 2023. Researchers wanted to understand the patients' backgrounds, previous treatments, and health conditions. The study did not test a new treatmen…

This study tested whether a special gel spacer placed near the rectum can help doctors aim radiation more accurately for prostate cancer. Seventeen men who already had the spacer and small metal markers (fiducials) were included. Doctors compared how well the gel spacer worked fo…

This study reviewed medical records from over 1,300 men with metastatic prostate cancer that still responds to hormone therapy. Researchers wanted to see how long patients actually take the pills apalutamide or enzalutamide when prescribed by their own doctors in routine care. Th…

This study tested a program for adults aged 65-90 who had breast, colorectal, or prostate cancer. A community health worker assessed their health and provided coaching to address issues often missed after cancer treatment. The goal was to see if the program was feasible and could…

This completed study created a biobank of saliva, tumor tissue, and questionnaire data from 592 African American men with prostate cancer in Florida. Researchers want to see if smoking is linked to more aggressive prostate cancer. Participants filled out surveys and provided samp…

This study looked at how DNA from tumors changes in the blood before, during, and after surgery for breast, prostate, or colon cancer. Thirty adults having curative surgery provided blood samples to measure these DNA levels. The goal was to understand the natural pattern of DNA c…

This study looked at whether a blood test could predict how prostate cancer responds to the drug abiraterone. Instead of taking a tissue sample (biopsy), researchers measured tumor cells circulating in the blood of 40 men with advanced prostate cancer. The goal was to see if chan…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This pilot study tested a patient navigator program for African-American adults with breast or prostate cancer. The goal was to see if having a navigator helps patients understand their treatment options and complete radiation therapy as planned. The study enrolled 30 people and …

This early-phase study looked at whether giving a single, short course of the drug flutamide can create DNA breaks in prostate cancer cells. The 25 participants were already receiving standard hormone therapy and brachytherapy (internal radiation). The goal was to see if this app…

This study observed over 1,000 Chinese patients with ovarian or prostate cancer who were already taking or starting the drug olaparib. Researchers tracked side effects and how doctors managed them in everyday practice. The goal was to better understand the drug's safety in this s…

This study looked at over 257,000 Swedish men aged 75-79 to see if PSA blood tests for prostate cancer reduce deaths. Since no clinical trials have tested this age group, researchers used existing health records to compare screened and unscreened men. The goal is to find out if s…

This study followed 30 men aged 45-70 who had their prostate removed due to cancer. Researchers measured urine leakage by weighing pads over 24 hours and during a 1-hour activity test. The goal was to better understand how long and how severe incontinence lasts after surgery.

This completed study looked at whether special PET scans can predict how aggressive a person's prostate cancer is. Researchers compared scan features with tumor samples from 70 patients who had surgery. The goal was to see if imaging could replace or reduce the need for invasive …

This completed Phase 1 study tested how the antibiotic rifampicin changes the way the body processes HRS-5041, an experimental drug for prostate cancer. Sixteen healthy men took HRS-5041 with and without rifampicin to measure drug levels and safety. The goal was to understand pot…

This study looked at whether androgen deprivation therapy (ADT), a common hormone treatment for prostate cancer, affects how well the heart pumps. Researchers compared heart function in 18 men: some who had ADT, some who didn't, and some without cancer. They used ultrasound and e…

This small study looked at whether special MRI scans can help doctors adjust radiation treatment for high-risk prostate cancer. Only 5 men took part, all with aggressive cancer. The goal was to see if the MRI method was reliable enough to guide changes in radiation doses. Because…